Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer
-
Published:2021-06
Issue:6
Volume:41
Page:3091-3097
-
ISSN:0250-7005
-
Container-title:Anticancer Research
-
language:en
-
Short-container-title:Anticancer Res
Author:
KIMURA MICHIO,USAMI EISEKI,TERAMACHI HITOMI,YOSHIMURA TOMOAKI
Publisher
Anticancer Research USA Inc.
Subject
Cancer Research,Oncology,General Medicine